LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.03 -8.85

Buy Sell

Overview

Share price change

24h

Current

Min

1.03

Max

1.13

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+364.04% upside

Market Stats
By TradingEconomics
Market Cap	-1.1M 125M
Previous open	9.88
Previous close	1.03

News Sentiment

By Acuity

52%

48%

308 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 gru 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Marsh McLennan Agency Acquires Three Hawaii-Based Insurance Brokerages

1 gru 2025, 18:51 UTC

Major Market Movers

Shopify Stock Falls on Cyber Monday System Outages

1 gru 2025, 23:47 UTC

Market Talk

Nikkei May Rise on Bargain Hunting -- Market Talk

1 gru 2025, 23:27 UTC

Acquisitions, Mergers, Takeovers

Genting Bhd. Stake in Genting Malaysia Now at 73.13% Vs. 49.36% Ahead of Take Private Offer Made in October

1 gru 2025, 23:26 UTC

Acquisitions, Mergers, Takeovers

Genting Bhd.: Offer to Take Genting Malaysia Private Closed on Dec.1

1 gru 2025, 23:25 UTC

Acquisitions, Mergers, Takeovers

Bitcoin Rout Picks Up Steam as Investors Fret Over a New 'Crypto Winter' -- WSJ

1 gru 2025, 21:52 UTC

Acquisitions, Mergers, Takeovers

Wood Partners Announces Itochu Corp. Purchase of 19.5% of Wood Partners

1 gru 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

1 gru 2025, 21:41 UTC

Market Talk

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1 gru 2025, 21:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 gru 2025, 21:41 UTC

Market Talk

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1 gru 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Commercial Metals Expects to Close Foley Products Deal by End of 2025 >CMC

1 gru 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Commercial Metals Completes Acquisition of Concrete Pipe & Precast for $675M Cash >CMC

1 gru 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Commercial Metals Completes Acquisition Of Concrete Pipe & Precast, LLC >CMC

1 gru 2025, 20:15 UTC

Market Talk

Natural Gas Turns Positive Amid Mixed Weather Trends -- Market Talk

1 gru 2025, 20:00 UTC

Acquisitions, Mergers, Takeovers

Marsh McLennan Agency Acquires Three Hawai'i-based Insurance Brokerages >MMC

1 gru 2025, 18:54 UTC

Market Talk

Silver Hits New Record As Momentum Continues -- Market Talk

1 gru 2025, 18:46 UTC

Market Talk

Luxury Seen With Accelerating Growth Next Year -- Market Talk

1 gru 2025, 16:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 gru 2025, 16:41 UTC

Market Talk

Rapid Wage Growth in Canada to Keep BOC Sidelined -- Market Talk

1 gru 2025, 16:20 UTC

Market Talk

Yen Could Strengthen Further Against Dollar on Rate-Hike Prospects -- Market Talk

1 gru 2025, 16:00 UTC

Earnings

Strategy Helped Solve Its Bitcoin-Preferred Problem. Here's How. -- Barrons.com

1 gru 2025, 15:51 UTC

Acquisitions, Mergers, Takeovers

Goldman Makes a $2 Billion Bet on 'Boomer Candy' -- WSJ

1 gru 2025, 15:47 UTC

Market Talk

Global Equities Roundup: Market Talk

1 gru 2025, 15:47 UTC

Market Talk

Airbus Guidance Is at Risk -- Market Talk

1 gru 2025, 15:46 UTC

Acquisitions, Mergers, Takeovers

Synopsys Gets a New Investor. What to Know About Nvidia's Stake. -- Barrons.com

1 gru 2025, 15:33 UTC

Market Talk

Airbus Selloff May Be Overdone -- Market Talk

1 gru 2025, 15:26 UTC

Market Talk

Warming Forecast Pressures Natural Gas -- Market Talk

1 gru 2025, 15:23 UTC

Market Talk

Geopolitical Turmoil Supports Crude Oil -- Market Talk

1 gru 2025, 14:59 UTC

Acquisitions, Mergers, Takeovers

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

364.04% upside

12 Months Forecast

Average 5.29 USD 364.04%

High 8 USD

Low 2 USD

Based on 9 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

308 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.